WHO latest COVAX news release
https://www.who.int/news/item/08-04-2021-covax-reaches-over-100-economies-42-days-after-first-international-delivery
First international delivery, Ghana, 24 February 2021
Now delivered vaccines to over 100 economies
So far, 38 million doses of vaccines
AstraZeneca, Pfizer-BioNTech and Serum Institute of India
Delays in planned deliveries for March and April
As of 13th April
https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/
797 doses given in 154 countries
Now, 18 million per day
For a further 7 billion people, needing 2 doses
Over two years
WHO, Solidarity trials
12 000 patients in 500 hospital sites in over 30 countries
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
found that all 4 treatments evaluated
remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon
had little or no effect on overall
mortality
initiation of ventilation
duration of hospital stay in hospitalized patients
The Solidarity Trial is considering evaluating other treatments, to continue the search for effective COVID-19 therapeutics
So far, only corticosteroids have been proven effective against severe and critical COVID-19.
WHO advises that ivermectin only be used to treat COVID-19 within clinical trials
https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials
https://www.forbes.com/sites/jvchamary/2021/01/31/remdesivir-covid-coronavirus/?sh=6a517c1c66c2
UK bases Recovery trial
https://www.recoverytrial.net
https://www.bmj.com/content/370/bmj.m2670
Azithromycin
https://www.recoverytrial.net/results/azithromycin-results
RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19
Convalescent Plasma
https://www.recoverytrial.net/results/convalescent-plasma
Data Monitoring Committee saw no convincing evidence that further recruitment would provide conclusive proof of worthwhile mortality benefit
Dexamethasone
https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf
Dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
Hydroxychloroquine
https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
Lopinavir-ritonavir
https://www.recoverytrial.net/results/lopinavar-results
No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients
Tocilizumab
https://www.recoverytrial.net/results/tocilizumab-results
Tocilizumab reduces deaths when given to hospitalised patients with severe COVID-19
Shortens time until patients are successfully discharged from hospital
Reduces the need for a mechanical ventilator
Pharmacy Magazine, ivermectin article
https://www.pharmacymagazine.co.uk/ivermectin-for-covid-19-a-cheap-drug-with-a-remarkable-effect
Introduced in 1981
Antiviral and anti-inflammatory properties
Some 4 billion doses have been taken over the past 40 years
Good safety record with minimal toxic effects
WHO Model List of Essential Medicines as a 3mg tablet
Countries now including ivermectin in their Covid-19 management strategies
Greece, Bulgaria, Macedonia, Slovakia, Czech Republic
Front Line Covid-19 Critical Care (FLCCC) Alliance
Called for the rapid introduction of ivermectin to stem the tide of infections
Prophylactic treatment can be given with two doses of 0.2mg/kg, 48 hours apart, once a month.
For early out-patient treatment, a daily dose of 0.2mg/kg for a maximum of five days is recommended
In the UK, the best way forward would be for the MHRA to authorise use of ivermectin for prophylaxis and treatment of Covid-19 on the basis of the published evidence to date.
Next, the drug could be made available through community pharmacies either using a PGD or by making ivermectin a P medicine
Ivermectin would then help to save lives and reduce suffering until the majority of the population can be vaccinated
Failure to use a cheap, safe drug that reduces the severity and duration of infection as well as the risks of death and transmission seems incomprehensible
Facebook, Partly false information
Ivermectin isn’t a highly effective drug for treating COVID-19
Current NICE guidelines
https://www.nice.org.uk/guidance/ng191/resources/covid19-rapid-guideline-managing-covid19-pdf-66142077109189
Source